Abstract
AbstractThe clinical importance of germline variants in DNA repair genes (DRGs) is becoming increasingly recognized, but their impact on advanced prostate cancer prognosis remains unclear. A cohort of 221 newly diagnosed metastatic castration-resistant prostate cancer (mCRPC) patients were screened for pathogenic germline variants in 114 DRGs. The primary endpoint was progression-free survival (PFS) on first-line androgen signaling inhibitor (ARSI) treatment for mCRPC. Secondary endpoints were time to mCRPC progression on initial androgen deprivation therapy (ADT) and overall survival (OS). Twenty-seven patients (12.2%) carried a germline DRG variant. DRG carrier status was independently associated with shorter PFS on first-line ARSI [HR 1.72 (1.06–2.81), P = 0.029]. At initiation of ADT, DRG carrier status was independently associated with shorter progression time to mCRPC [HR 1.56, (1.02–2.39), P = 0.04] and shorter OS [HR 1.99, (1.12–3.52), P = 0.02]. Investigating the contributions of individual germline DRG variants on PFS and OS revealed CHEK2 variants to have little effect. Furthermore, prior taxane treatment was associated with worse PFS on first-line ARSI for DRG carriers excluding CHEK2 (P = 0.0001), but not for noncarriers. In conclusion, germline DRG carrier status holds independent prognostic value for predicting advanced prostate cancer patient outcomes and may potentially inform on optimal treatment sequencing already at the hormone-sensitive stage.
Funder
Novo Nordisk Fonden
Kræftens Bekæmpelse
Harboefonden
The Graduate School of Health, Aarhus University
Christian og Ottilia Brorsons Travel Grant
Rosetrees Trust
Cancer Research UK
Prostate Cancer UK
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Leongamornlert, D. et al. Germline BRCA1 mutations increase prostate cancer risk. Br. J. Cancer 106, 1697–1701. https://doi.org/10.1038/bjc.2012.146 (2012).
2. Ryan, S., Jenkins, M. A. & Win, A. K. Risk of prostate cancer in Lynch syndrome: A systematic review and meta-analysis. Cancer Epidemiol. Biomark. Prev. 23, 437–449. https://doi.org/10.1158/1055-9965.EPI-13-1165 (2014).
3. Wang, Y., Dai, B. & Ye, D. CHEK2 mutation and risk of prostate cancer: A systematic review and meta-analysis. Int. J. Clin. Exp. Med. 8, 15708–15715 (2015).
4. Zhen, J. T. et al. Genetic testing for hereditary prostate cancer: Current status and limitations. Cancer 124, 3105–3117. https://doi.org/10.1002/cncr.31316 (2018).
5. Pritchard, C. C. et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375, 443–453. https://doi.org/10.1056/NEJMoa1603144 (2016).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献